Fermer le menu


Member of Lyonbiopole


Dermadis is a Biotech company developing breakthrough drugs to treat inflammatory skin disorders by controlling specific biological pathways. Dermadis’ lead  compound is currently in final preclinical development for the severe orphan disease Netherton Syndrome. For this indication Dermadis has received  Orphan Drug Designation status by the EMEA and FDA.

Additionally, Dermadis' compound family based on engineered forms of human proteins (biomimetics) has also confirmed potential in related large market dermatology indications (e.g. atopic dermatitis or rosacea) and various skin conditions (e.g. reactive skin, sensitive skin, itchy skin). Therefore, Dermadis has set up collaborations with companies active in dermo-cosmetics and veterinary medicine in order to supply them with such active ingredients.


Strategic application domain: Human Medicine

Type of activity: Therapeutics, Pharma or Biotech

Technologies: Antibodies - Protein - Peptide

Created on march 15th, 2010 - 5 employees



Avenue Marie Curie 218, Archamps Technopole 74160 Archamps



Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.